I spoke with endocrinologist and diabetes tech expert Dr. David Ahn at the ATTD conference about the biggest breakthroughs shaping the future of diabetes management, including the rapid progress toward fully closed-loop insulin delivery systems. We explored how companies like MiniMed, CamAPS, and Omnipod are advancing automation that reduces carb counting, minimizes manual bolusing, and improves time-in-range outcomes. We also discussed emerging topics such as GLP-1 therapies for type 1 diabetes, AI-powered diabetes tools, and continuous glucose-plus-ketone monitoring aimed at preventing diabetic ketoacidosis. We shared key takeaways from ATTD and what these innovations mean for reducing daily diabetes burden while moving closer to a true artificial pancreas.

DISCLAIMER: This podcast is not medical advice and is for educational purposes only. Always consult with your doctor before making changes to your health care.

*10-day trial eligibility may vary. Full terms and conditions apply. Visit omnipod.com/diabetech for clinical disclaimers, terms and important safety information. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.

ATTD 2026: Biggest Diabetes Tech News Roundup